Sumitomo grants Maruishi rights to FAAH inhibitor

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) granted Maruishi Pharmaceutical Co. Ltd. (Osaka, Japan) exclusive development and commercialization rights to a preclinical fatty acid amide hydrolase (FAAH) inhibitor. The compound is testing in the U.S. and Japan to treat nausea and vomiting. Sumitomo Dainippon will receive an upfront payment and is eligible for milestones and royalties...